Ibrutinib Cessation Following Prolonged Exposure Supports Intermittent Investigation in CLL
Stable peripheral disease levels lasting 12 months were reported in patients with treatment-naïve chronic lymphocytic leukemia following 6 years of continuous treatment with ibrutinib.
Source: onclive.com